SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U. flu immunisation rates, which knocked its ...
The head of an Australian biotech business has blamed lower vaccination rates in the US as a key factor behind the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback